Table 3.
RET fusions in lung cancer.
| RET fusion | Locus of the partner gene | End exon of the partner gene | Start exon of RET | Reference | #cases | age | Sex | Country/race | Histopathology | EGFR mutation | KRAS mutation | Other driver mutation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KIF5B-RET | 10p11.22 | – | – | Ju et al., 2012 | 3 | – | – | Korea | Adenocarcinoma | 0/3 | 0/2 | Negative for EML4-ALK |
| – | – | Kohno et al., 2012 | 7 | – | – | 6 Japan, 1 United States | Adenocarcinoma | 0/7 | 0/7 | Negative for HER2 mutation and ALK rearrangement | ||
| – | – | Takeuchi et al., 2012 | 12 | – | – | Japan | Adenocarcinoma | 0/12 | 0/12 | Negative for ALK and ROS1 rearrangements | ||
| – | – | Lipson et al., 2012 | 12 | – | – | NA | Adenocarcinoma | 0/12 | 0/12 | Negative for ERBB2 and BRAF mutations, EML4-ALK, and ROS1 rearrangements | ||
| CCDC6-RET | 10q21.2 | 1 | 12 | Takeuchi et al., 2012 | 2 | – | – | Japan | Adenocarcinoma | 0/2 | 0/2 | Negative for ALK and ROS1 rearrangements |
| NCOA4-RET | 10q11.23 | 6 | 12 | Wang et al., 2012 | 1 | 80 | F | NA | Adenocarcinoma | 0/1 | 0/1 | Negative for ALK rearrangement |
| TRIM33-RET | 1p13.2 | 14 | 12 | Drilon et al., 2013 | 1 | 41 | F | Caucasian | Adenocarcinoma | 0/1 | 0/1 | Negative for NRAS, BRAF, HER2, PIK3CA, MAP2K1, and AKT mutations and ALK and ROS1 rearrangements |
| RUFY2-RET | 10q21.3 | 9 | 12 | Zheng et al., 2014 | 1 | NA | NA | NA | Adenocarcinoma | 0/1 | 0/1 | Negative for aberrations in otder driver genes detectable witd tde system |
| CUX1-RET | 7q22.1 | 10 | 12 | Lira et al., 2014 | 1 | 49 | M | Korea | Adenocarcinoma (solid) | 0/1 | 0/1 | Negative for ALK and ROS1 rearrangements |
| KIAA1468-RET | 18q21.33 | 10 | 12 | Nakaoku et al., 2014 | 1 | 62 | M | Japan | Adenocarcinoma (invasive musinous) | 0/1 | 0/1 | Negative by RNA sequencing |
| CLIP1-RET | 12q24.31 | NA | NA | Drilon et al., 2016 | 1 | NA | NA | NA | NA | NA | NA | NA |
| ERC1-RET | 12p13.33 | NA | NA | Drilon et al., 2016 | 1 | NA | NA | NA | NA | NA | NA | NA |
| MYO5C-RET | 15q21.2 | 25 | 12 | Lee S.H. et al., 2017 | 1 | NA | NA | NA | Adenocarcinoma | 0/1 | NA | Negative for ALK rearrangement |
| EPHA5-RET | 4q13.1-q13.2 | NA | NA | Gautschi et al., 2017 | 1 | NA | NA | NA | NA | NA | NA | NA |
| PICALM-RET | 11q14.2 | NA | NA | Gautschi et al., 2017 | 1 | NA | NA | NA | NA | NA | NA | NA |
| FRMD4A-RET | 10p13 | 12 | 12 | Velcheti et al., 2017 | 1 | 65 | F | white | Non-small cell carcinoma (positive for TTF1 and napsin A, negative for p63 and CK5/6) | 0/1 | 0/1 | Negative for ALK and ROS1 rearrangements |
| KIF13A-RET | 6p22.3 | 18 | 12 | Zhang et al., 2018 | 1 | 74 | F | China | Adenocarcinoma | 0/1 | NA | Negative for ALK and ROS1 rearrangements |
| WAC-RET | 10p12.1 | 3 | 12 | Velcheti et al., 2018 | 1 | 62 | F | White | Adenocarcinoma | 0/1 | 0/1 | Negative for ALK rearrangement |